Usage / Dosage
1. Primary and secondary carnitine deficiency Myocardial metabolic disorders due to ischemic heart disease: angina pectoris, acute myocardial infarction
Adults: L-carnitine, 2-3 grams per day, divided into 2-3 divided doses, intramuscularly or intravenously. 
Increase or decrease appropriately according to age and symptoms.

2. In the initial stage of carnitine deficiency treatment for end-stage renal disease patients undergoing hemodialysis, 10-20 mg/kilogram should be administered intravenously over 2-3 minutes at the end of each hemodialysis.
However, the dose can be adjusted according to the plasma L-carnitine level before hemodialysis.

Precautions for use:
[Change of permission (safety information processing) Drug Safety Evaluation Division-463, 2019.01.23.]

1. Warning The ampoule injection may contain glass fragments when cutting the container, which may cause side effects, so be careful to minimize the mixing of glass fragments when using it. However, be especially careful when using children and the elderly.

2. Do not administer to the following patients. Patients with hypersensitivity to this drug

3. Side effects
Temporary nausea/vomiting, abdominal pain, diarrhea, and body odor may occur. Gastritis has been reported rarely, and seizures have been reported in patients receiving L-carnitine orally or intravenously. The frequency and intensity of seizures increased in patients with a prior history of seizures. In addition, the following side effects were reported regardless of causality in a double-blind, placebo-controlled trial in chronic hemodialysis patients.

​

​